<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:regsci-ojs-tamu.tdl.org:article/313</identifier>
				<datestamp>2025-12-10T15:15:52Z</datestamp>
				<setSpec>regsci:RC</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Risk Assessment and Regulatory Response to Systematic Pharmaceutical Quality Failures: Lessons from Argentina's Contaminated Fentanyl and Dexamethasone Crisis</dc:title>
	<dc:creator xml:lang="en">Bernaus, Carlos</dc:creator>
	<dc:subject xml:lang="en">pharmacovigilance</dc:subject>
	<dc:subject xml:lang="en">regulatory affairs</dc:subject>
	<dc:subject xml:lang="en">pharmaceutical adulteration</dc:subject>
	<dc:subject xml:lang="en">Regulatory affairs</dc:subject>
	<dc:subject xml:lang="en">good manufacturing practices</dc:subject>
	<dc:subject xml:lang="en">regulatory compliance</dc:subject>
	<dc:subject xml:lang="en">inyectable</dc:subject>
	<dc:subject xml:lang="en">fentanyl</dc:subject>
	<dc:subject xml:lang="en">pharmacovigilance</dc:subject>
	<dc:subject xml:lang="en">Quality Control</dc:subject>
	<dc:subject xml:lang="en">patient safety</dc:subject>
	<dc:subject xml:lang="en">Latinamerica</dc:subject>
	<dc:subject xml:lang="en">Argentina</dc:subject>
	<dc:subject xml:lang="en">adulteration</dc:subject>
	<dc:description xml:lang="en">The pharmaceutical industry operates under strict regulatory frameworks ensuring medicine safety, quality, and efficacy. In Argentina, the National Administration of Medicines, Food and Medical Technology (ANMAT) and other local jurisdictions oversee regulatory compliance through Good Manufacturing Practices (GMP) and quality control standards. Despite widespread industry commitment to patient safety, systematic failures by certain manufacturers can cause an unprecedented outbreak and major health crises. To examine quality incidents involving the products of a specific Marketing Authorization Holder (MAH) and its co-contracted manufacturing site between 2018 and 2025, to assess GMP and quality control deficiencies, regulatory responses, and legal responsibilities under Argentine Law 16.463 and provincial regulations culminating in a major pharmaceutical adulteration crisis in South America.</dc:description>
	<dc:publisher xml:lang="en">Office of the Texas State Chemist</dc:publisher>
	<dc:date>2025-12-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://regsci-ojs-tamu.tdl.org/regsci/article/view/313</dc:identifier>
	<dc:identifier>10.21423/JRS.REGSCI.131313</dc:identifier>
	<dc:source xml:lang="en">Journal of Regulatory Science; Vol. 13 No. 1 (2025)</dc:source>
	<dc:source>2377-3537</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/313/344</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2025 Carlos Bernaus</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
	
